These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 2659570

  • 1. FCE 22101 and FCE 22891: in-vitro antibacterial activity at concentrations simulating human plasma levels following intravenous, intramuscular and oral administration.
    Della Bruna C, Jabes D, Rossi R, Younes G, Castellani P.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():119-28. PubMed ID: 2659570
    [Abstract] [Full Text] [Related]

  • 2. In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents.
    Chin NX, Neu HC.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():95-101. PubMed ID: 2786520
    [Abstract] [Full Text] [Related]

  • 3. In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests.
    Barry AL, Jones RN, Thornsberry C.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():17-30. PubMed ID: 2732139
    [Abstract] [Full Text] [Related]

  • 4. In-vitro activity of the new penems FCE 22101 and FCE 24362 alone or in combination with aminoglycosides against streptococci isolated from patients with endocarditis.
    Dornbusch K, Henning C, Lindén E.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():109-17. PubMed ID: 2732133
    [Abstract] [Full Text] [Related]

  • 5. Comparative inhibitory and bactericidal activities of FCE 22101 against gram-positive cocci and anaerobes in vitro.
    Maskell JP, Tang T, Asad S, Williams JD.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():65-74. PubMed ID: 2732145
    [Abstract] [Full Text] [Related]

  • 6. In-vitro activity of a new penem FCE 22101.
    Hoban DJ.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():53-7. PubMed ID: 2786518
    [Abstract] [Full Text] [Related]

  • 7. Activity of FCE 22891 compared with cefuroxime axetil and cefixime in pulmonary and subcutaneous infections in mice.
    Rossi R, Castellani P, Younes G, Della Bruna C.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():149-55. PubMed ID: 2732136
    [Abstract] [Full Text] [Related]

  • 8. Lytic and bactericidal activity of FCE 22101.
    Jabes D, Tomasz A.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():75-83. PubMed ID: 2659573
    [Abstract] [Full Text] [Related]

  • 9. Activity of FCE 22101 against methicillin-resistant Staphylococcus aureus and affinity for penicillin binding proteins.
    Piddock LJ, Traynor EA, Wise R.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():59-64. PubMed ID: 2732144
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q, Wang J, Cui T, Yang Z, Su M, Zhao P, Yan H, Zhan Y, Yang H.
    Molecules; 2016 Jan 06; 21(1):62. PubMed ID: 26751436
    [Abstract] [Full Text] [Related]

  • 11. Antibacterial activity of FCE 22101 against relatively resistant blood culture isolates.
    Qadri SM, Ueno Y, Ellis ME.
    Chemotherapy; 1991 Jan 06; 37(1):15-22. PubMed ID: 2013238
    [Abstract] [Full Text] [Related]

  • 12. The pharmacokinetics and tissue penetration of FCE 22101 following intravenous and oral administration.
    Webberley JM, Wise R, Andrews JM, Ashby JP, Wallbridge D.
    J Antimicrob Chemother; 1988 Apr 06; 21(4):445-50. PubMed ID: 3378958
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of FCE 22101 in man following different modes of administration.
    Lovering AM, White LO, Lewis DA, MacGowan AP, Routh KR, Pickin DM, Reeves DS.
    J Antimicrob Chemother; 1989 Mar 06; 23 Suppl C():179-95. PubMed ID: 2732141
    [Abstract] [Full Text] [Related]

  • 14. Comparative in-vitro activity of the penem FCE 22101 against recent European blood culture isolates.
    Dornbusch K, Kronvall G, Göransson E, Mörtsell E.
    J Antimicrob Chemother; 1989 Mar 06; 23 Suppl C():43-52. PubMed ID: 2732143
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.
    Dornbusch K, Kronvall G, Göransson E, Mörtsell E.
    J Antimicrob Chemother; 1989 Mar 06; 23 Suppl C():31-41. PubMed ID: 2786517
    [Abstract] [Full Text] [Related]

  • 17. Application of in-vitro models: development of resistance.
    Seeberg AH, Wiedemann B.
    J Antimicrob Chemother; 1985 Jan 06; 15 Suppl A():241-9. PubMed ID: 3884569
    [Abstract] [Full Text] [Related]

  • 18. Bactericidal activity of meropenem and interactions with other antibiotics.
    Ferrara A, Grassi G, Grassi FA, Piccioni PD, Gialdroni Grassi G.
    J Antimicrob Chemother; 1989 Sep 06; 24 Suppl A():239-50. PubMed ID: 2808210
    [Abstract] [Full Text] [Related]

  • 19. Interactions of FCE 22101 with class I beta-lactamases.
    Yang Y, Livermore DM.
    J Antimicrob Chemother; 1989 Mar 06; 23 Suppl C():85-94. PubMed ID: 2786519
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.